close :

:

Forgotten your password?
 
Pharma Industry News
Printable Version   Email to a friend

Consumer Reports Poll: Most Say TV Drug Ads Should Include Info on How to Report Side Effects

Most Americans Don't Know They Can Report Bad Reactions to FDA Safety Program

WASHINGTON, April 02, 2008, 2008 /PRNewswire-USNewswire/ -- A new poll shows that one in six Americans who have ever taken a prescription drug experienced a side effect serious enough to send them to the doctor or hospital, but the majority of consumers don't know they can report these side effects to the FDA, which is responsible for tracking drug safety problems.

To help make the public aware of the FDA's reporting program for drug side effects -- known as MedWatch -- Consumers Union today gave the FDA a petition signed by nearly 56,000 consumers asking that a toll-free number and website be included in all TV drug ads so people can easily report their serious side effects to the agency. CU is the nonprofit publisher of .

"You can't turn on a TV today without seeing a drug ad, but those ads never mention that consumers should be reporting serious drug side effects to the FDA," said Liz Foley, campaign coordinator with Consumers Union. "What better way for the FDA to let consumers know how to report serious problems with their medications than putting a toll-free number and website in all those drug ads we're bombarded by each day?"

Congress required the MedWatch reporting information in all print drug ads when it approved a major overhaul of drug safety laws last fall, and called for an FDA study to determine if it was appropriate to include the information in TV advertisements. But that study -- due at the end of March -- has not been completed.

"As someone who lost a loved one from an adverse drug reaction but didn't know where to turn, the FDA should make it as easy as possible for people to report serious side effects," said Kim Witczak, founder of the drug safety advocacy group WoodyMatters, named after her husband.

Witczak worked with Rep. Jan Schakowsky (D-Ill.) and others to get the DTC reporting language in last fall's FDA reform bill. "If the FDA is really serious about finding out how drugs work in the millions of people who take them each day, it should be doing all it can to make sure the reporting information is included in the advertising -- not dragging its feet," Witczak said.

A national poll by the Consumer Reports National Research Center found that among consumers who have ever taken a prescription drug, one in six (16 percent) had experienced a serious drug side effect at some time in their life -- described by the FDA as a reaction that led them to visit a doctor or hospital, was life-threatening or caused a significant disability or incapacity. But only 35 percent of consumers polled were aware that serious side effects can be reported to the FDA. (To view the poll, go to http://www.ConsumersUnion.org).

Yet Americans were very familiar with drug advertising. Eight in 10 (81 percent) said they had seen or heard an advertisement for prescription drugs within the past 30 days. Among them, virtually all -- 98 percent -- viewed an ad on television.

When asked if they think prescription drug advertising should include information to report an adverse drug reaction to the FDA, 87 percent of consumers said TV ads should contain the information, and 90 percent said print ads should do the same.

"Clearly, consumers want to know how to report serious drug side effects to the FDA, and they think drug advertising is an ideal way to do that," Foley said.

Adverse event reporting by consumers is vital to signaling drug safety problems, but the FDA's reporting system, MedWatch, catches only a fraction of serious side effects. In 2004, about 423,000 adverse events were collected by the FDA, even though drug reactions account for nearly 700,000 emergency room visits each year.

Drug makers are required to report adverse events to the FDA, yet doctors and patients -- those with the most direct experience with side effects -- voluntarily report them, and little is done by the FDA to make consumers aware of how to report side effects.

An Institute of Medicine report found that in 2004, only 21,500 of the more than 422,000 reports that year came from doctors and patients.

The survey asked consumers if they would know where to report a serious side effect -- 72 percent said they would. Among them, the vast majority (79 percent) said they would report their problems to their doctor, followed by their pharmacist at 16 percent. Only 7 percent of that group said they would file a report with the FDA.

"Doctors and health care professionals play an important role in drug safety when they report their patients' adverse reactions to the FDA. But we're aware of the demands on their time, and we think consumers should know there is a resource available at the FDA to track their severe drug reactions," Foley said.

CONTACT: Susan Herold, +1-202-462-6262, or Liz Foley, +1-914-378-2421,both of Consumers Union; or Kim Witczak of WoodyMatters, +1-612-877-0570

Terms and conditions of use apply
Copyright © 2008 PR Newswire Association LLC. All rights reserved.
A United Business Media Company

Latest Pharma Industry News...

Pharma Industry News Archive

2008: Jan | Feb | Mar | Apr | May | Jun | Jul
2007: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2006: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2005: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2004: Jan | Feb | Mar | Apr | May | Jul | Aug | Sep | Oct | Nov | Dec
2003: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2002: Jan | Apr | May | Jun | Aug | Sep | Oct | Nov | Dec

More News Resources


Most Popular Internet Searches
Latest FDA Drug Alerts
July 24, 2008
Audience: Infectious disease and medical genetics healthcare professionals[Posted 07/24/2008] FDA informed healthcare...
July 17, 2008
Audience: Radiological healthcare professionals, cardiologists, hospital risk managers [Posted 07/17/2008] FDA is updating...
July 16, 2008
Audience: Radiologists, surgeons, hospital risk managers, other healthcare professionals [Posted 07/16/2008] FDA informed...
July 16, 2008
Audience: Pharmacists, hospital risk managers, other healthcare professionals[Posted 07/16/2008] Roxane Laboratories, Inc....
More...
Latest Drug Information Updates

Eovist
Eovist (gadoxetate disodium) is a gadolinium-based contrast agent for intravenous use in T1-weighted magnetic resonance imaging (MRI) of the liver to detect and characterize lesions in adults with known or suspected focal liver disease.

Evolence
Evolence is a collagen-based structural dermal filler for the correction of moderate to deep facial wrinkles and folds, such as nasolabial folds.

Kinrix
Kinrix [Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed and Inactivated Poliovirus Vaccine] is a combination vaccine for protection against diphtheria, tetanus, pertussis and polio diseases in children.

Durezol
Durezol (difluprednate ophthalmic emulsion) is a topical steroid for the treatment of postoperative ocular inflammation and pain.

PrandiMet
PrandiMet (repaglinide and metformin HCl) is a fixed-dose combination of the fast-acting secretagogue replaglinide (also known as Prandin) and insulin sensitizer, metformin, indicated for the treatment of type 2 diabetes.

Pentacel
Pentacel is a combination vaccine indicated for active immunization against diphtheria, tetanus, pertussis, poliomyelitis and invasive disease due to Haemophilus influenzae type b in children 6 weeks through 4 years of age.

Trivaris
Trivaris (triamcinolone acetonide) is a glucocorticoid corticosteroid delivered via intravitreal injection for the treatment of sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids.

Entereg
Entereg (alvimopan) is a peripherally-acting mu opioid receptor antagonist used to help patients regain gastrointestinal (GI) function earlier following bowel resection surgery.

OraVerse
OraVerse is a dental anesthetic reversal agent that accelerates the return to normal sensation and function following dental procedures.

Aplenzin
Aplenzin is a once-daily formulation of bupropion hydrobromide indicated for the treatment of depression in adults.

Cimzia
Cimzia is a PEGylated anti-TNF (tumor necrosis factor) biologic therapy for the treatment of moderately to severely active Crohn’s disease in adults.

Relistor
subcutaneous injection for the treatment of opioid-induced constipation

Treximet
Treximet is the first and only migraine product designed to target multiple mechanisms of migraine by combining a triptan, a class of migraine-specific medicines, and an anti-inflammatory pain reliever in a single tablet.

Patanase
Patanase (olopatadine) is an antihistamine nasal spray for the treatment of symptoms of seasonal allergic rhinitis in adults and adolescents twelve years of age and older.

Lexiscan
Lexiscan (regadenoson) is an A2A adenosine receptor agonist indicated for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging (MPI), a test that detects and characterizes coronary artery disease, in patients unable to undergo adequate exercise stress.

More...